Asymptomatic pre-malignant disorder associated with relatively low risk (on average 0.5% to 1.0% per year) of progression to multiple myeloma or related plasma cell proliferative malignancies.
No aetiological risk factors have been defined. Male sex, older age, family history of monoclonal gammopathy of undetermined significance, African ancestry, and exposure to radiation or pesticide are associated with a higher prevalence.
There is no indication for specific treatment. Clinical- and laboratory-based follow up is recommended.
Monoclonal gammopathy of undetermined significance (MGUS) is an asymptomatic disorder associated with an increased risk of developing multiple myeloma and related plasma cell proliferative malignancies. The following criteria must be met for diagnosis: presence of a monoclonal (M) protein in the serum (at a concentration <30 g/L [3 g/dL]) or in urine (<500 mg per 24 hours); <10% plasma cells in the bone marrow (a bone marrow examination is only required if M protein is >15 g/L [1.5 g/dL], or for non-IgG MGUS, or if the free light chain ratio is abnormal); and an absence of lytic bone lesions, anaemia, hypercalcaemia, renal insufficiency, or amyloidosis related to the plasma cell proliferative process.
History and exam
Professor of Medicine
Division of Hematology
SK has served as a consultant for Janssen, Abbvie, Amgen, Merck, Celgene, Takeda, and Skyline.
Professor Shaji Kumar would like to gratefully acknowledge Dr Ola Landgren, a previous contributor to this topic. OL is an author of several references cited in this topic.
Section of Haemato-Oncology
Brookes Lawley Institute of Cancer
DC declares that he has no competing interests.
Use of this content is subject to our disclaimer